The affinity and kinetics of inhibition of cysteine proteinases by intact recombinant bovine cystatin C.
Recent studies have shown that the bovine cysteine proteinase inhibitor, cystatin C, is synthesized as a preprotein containing a 118-residue mature protein. However, the forms of the inhibitor isolated previously from bovine tissues had shorter N-terminal regions than expected from these results, and also lower affinity for proteinases than human cystatin C. In this work, we report the properties of recombinant, full-length bovine cystatin C having a complete N-terminal region. The general characteristics of this form of the inhibitor, as reflected by the isoelectric point, the far-ultraviolet circular dichroism spectrum, the thermal stability and the changes of tryptophan fluorescence on interaction with papain, resembled those of human cystatin C. The affinity and kinetics of inhibition of papain and cathepsins B, H and L by the bovine inhibitor were also comparable with those of the human inhibitor, although certain differences were apparent. Notably, the affinity of bovine cystatin C for cathepsin H was somewhat weaker than that of human cystatin C, and bovine cystatin C bound to cathepsin L with about a four-fold higher association rate constant than the human inhibitor. This rate constant is comparable with the highest values reported previously for cystatin-cysteine proteinase reactions. The full-length, recombinant bovine cystatin C bound appreciably more tightly to proteinases than the shorter form characterized previously. Digestion of the recombinant inhibitor with neutrophil elastase resulted in forms with truncated N-terminal regions and appreciably decreased affinity for papain, consistent with the forms of bovine cystatin C isolated previously having arisen by proteolytic cleavage of a mature, full-length inhibitor.
Olsson
S L
SL
Department of Veterinary Medical Chemistry, Swedish University of Agricultural Sciences, Uppsala Biomedical Center, Box 575, SE-751 23, Uppsala, Sweden. sigrid-lisa.olsson@vmk.slu.se
Ek
B
B
Björk
I
I
D000818:Animals; D002401:Cathepsin B / Q000037:antagonists & inhibitors; D056655:Cathepsin H; D002403:Cathepsins / Q000037:antagonists & inhibitors / Q000494:pharmacology; D002417:Cattle; D002942:Circular Dichroism; D055316:Cystatin C; D015891:Cystatins / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D003546:Cysteine Endopeptidases / Q000494:pharmacology; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D004926:Escherichia coli / Q000378:metabolism; D007700:Kinetics; D010206:Papain / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000494:pharmacology; D013696:Temperature
C525030:CST3 protein, human; D055316:Cystatin C; D015891:Cystatins; D015853:Cysteine Proteinase Inhibitors; D011994:Recombinant Proteins; D002403:Cathepsins; D003546:Cysteine Endopeptidases; D002401:Cathepsin B; C534126:CTSH protein, human; D056655:Cathepsin H; D010206:Papain